A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy

Exclusion Criteria

• •1. Patients with peripheral nervous system disorders caused by diseases or those with a history of significant mental and central nervous system disorders;\<p\>
• •2. Patients with severe infections or active digestive ulcers requiring treatment;\<p\>
• •3. Those who are allergic to relevant therapeutic drugs or have surgical contraindications;\<p\>
• •4. Patients with other malignant tumors within the past 5 years, except for cured skin basal cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma, and other malignant tumors;\<p\>
• •5. Those whose heart function meets any of the following criteria: 1) Left ventricular ejection fraction (LVEF)\<50% (detected by echocardiography). 2) The New York Heart Association (NYHA) has a heart function classification of ≥ II. 3) Clinically significant arrhythmias require drug treatment. 4) An acute myocardial infarction occurred within the 6 months prior to enrollment. 5) Uncontrolled hypertension (systolic blood pressure\>160 mmHg or diastolic blood pressure\>100 mmHg). 6) Other heart diseases that have been determined by researchers to be unsuitable for treatment with anthracyclines.\<p\>
• •6. Severe liver disease (such as cirrhosis), kidney disease, respiratory disease, blood system disease or uncontrollable diabetes;\<p\>
• •7. There are patients infected with hepatitis B, hepatitis C, syphilis and AIDS;\<p\>
• •8. Patients who relapse within 6 months after adjuvant chemotherapy;\<p\>
• •9. During the adjuvant therapy period, the cumulative equivalent dose of doxorubicin is greater than 120mg/m2;\<p\>
• •10. Patients who are currently participating or have participated in other clinical trials within the past month;\<p\>
• •11. Patients deemed unsuitable for inclusion by researchers.